174 related articles for article (PubMed ID: 37657484)
1. Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding.
Yu J; Wang T; Zhang X; Chen Q; Hu Y; Liang Q; Shi Y; Wang Y; Zhang Y; Yu M; Zhao B
Thromb Haemost; 2024 Feb; 124(2):108-121. PubMed ID: 37657484
[TBL] [Abstract][Full Text] [Related]
2. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W
Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902
[TBL] [Abstract][Full Text] [Related]
3. Novel antithrombotic drugs in development.
Verstraete M; Zoldhelyi P
Drugs; 1995 Jun; 49(6):856-84. PubMed ID: 7641602
[TBL] [Abstract][Full Text] [Related]
4. Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection.
Chen S; Lv K; Sharda A; Deng J; Zeng W; Zhang C; Hu Q; Jin P; Yao G; Xu X; Ming Z; Fang C
Pharmacol Res; 2021 May; 167():105540. PubMed ID: 33711433
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
6. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
7. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
8. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
Mehta AY; Mohammed BM; Martin EJ; Brophy DF; Gailani D; Desai UR
J Thromb Haemost; 2016 Apr; 14(4):828-38. PubMed ID: 26748875
[TBL] [Abstract][Full Text] [Related]
9. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
10. Intravenously administered APAC, a dual AntiPlatelet AntiCoagulant, targets arterial injury site to inhibit platelet thrombus formation and tissue factor activity in mice.
Bonetti NR; Jouppila AS; Saeedi Saravi SS; Cooley BC; Pasterk L; Liberale LL; Gobbato S; Lüscher TF; Camici GG; Lassila RP; Beer JH
Thromb Res; 2023 Aug; 228():163-171. PubMed ID: 37331119
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
[TBL] [Abstract][Full Text] [Related]
14. Diindolylmethane ameliorates platelet aggregation and thrombosis: In silico, in vitro, and in vivo studies.
Ramakrishna K; Singh N; Krishnamurthy S
Eur J Pharmacol; 2022 Mar; 919():174812. PubMed ID: 35151647
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic drugs: part I.
Gallus AS; Hirsh J
Drugs; 1976; 12(1):41-68. PubMed ID: 789043
[TBL] [Abstract][Full Text] [Related]
18. VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.
Sivaraja M; Clemens DM; Sizikov S; Dash S; Xu C; Rienzo M; Yang B; Ryan M; Chattopadhyay M; Igoudin L; Chang SS; Keutzer S; Zalicki P; Estiarte MA; Shiau TP; Short KM; Williams DC; Datta A; Pozzi N; Di Cera E; Gibson CM; Fox KAA; Kita DB
Thromb Res; 2020 Jun; 190():112-121. PubMed ID: 32339947
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor.
Giardino EC; Costanzo MJ; Kauffman JA; Li QS; Maryanoff BE; Andrade-Gordon P
Thromb Res; 2000 Apr; 98(1):83-93. PubMed ID: 10706936
[TBL] [Abstract][Full Text] [Related]
20. Cinnamaldehyde reduction of platelet aggregation and thrombosis in rodents.
Huang J; Wang S; Luo X; Xie Y; Shi X
Thromb Res; 2007; 119(3):337-42. PubMed ID: 16626787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
